The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).
 
Zhen Shi
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Sergio Bracarda
Consulting or Advisory Role - Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis/Ipsen; Ipsen; Janssen Oncology; Pfizer; Roche
 
Cora N. Sternberg
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Ipsen; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Incyte; Ipsen; Medscape; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; UroToday
Research Funding - Aragon Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Myovant Sciences (Inst); Nektar (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Kim N. Chi
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; ESSA; Janssen; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
 
David Olmos
Honoraria - Astellas Pharma (Inst); Bayer; Janssen
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Bayer (Inst); Clovis Oncology; Janssen; Janssen (Inst)
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen
 
Shahneen Kaur Sandhu
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Merck Serono
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; Orion; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical
 
Nobuaki Matsubara
Consulting or Advisory Role - Janssen; Sanofi
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Marie-Laurence Harle-Yge
Employment - Roche
 
Malgorzata Nowicka
Employment - Roche
 
Matthew Wongchenko
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex